TICKERNERD
Menu
ANIXANIXHealthcare · Biotechnology

ANIX Stock Forecast: Anixa Biosciences, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$3.71
+3.20% on the day

The 4 Wall Street analysts covering Anixa Biosciences, Inc. hold a median 12-month price target of $9.5 — +156.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 85 of 100 as at 22 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$122.1M
Ticker Nerd rank
85 / 100
Median analyst target
$9.50
Analysts covering
4
Total return, dividends reinvested
1W
+16.5%
1M
+4.1%
YTD
+18.8%
1Y
+25.6%
From 52W high
−29.0%
From 52W low
+57.7%
$2.35
$5.22
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ANIX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Anixa Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
85 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
93
Value
81
Size
73
Revisions
67
Growth
65
Accruals
62
Momentum
59
Issuance
55
Quality
44

Volatility (93): The share price has been relatively steady.

Quality (44): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ANIX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ANIX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$4.00$6.00$8.00$10.00$12.00$14.00Oct 25Jan 26Apr 26Jul 26ANIXHigh $14.00Median $9.50Low $7.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $7.00Median $9.50High $14.00

The green dot is the last close — the median target sits +156.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
30 June 2026D. Boral CapitalAssumesBuy$10
8 Apr 2026D. Boral CapitalMaintainsBuy—
31 Mar 2026D. Boral CapitalMaintainsBuy—
4 Feb 2026D. Boral CapitalMaintainsBuy—
12 Dec 2025D. Boral CapitalMaintainsBuy—
7 Oct 2025D. Boral CapitalMaintainsBuy—
22 Sept 2025D. Boral CapitalMaintainsBuy—
11 Sept 2025HC Wainwright & Co.ReiteratesBuy—
9 Sept 2025D. Boral CapitalMaintainsBuy—
19 Aug 2025D. Boral CapitalMaintainsBuy—
5 Aug 2025D. Boral CapitalMaintainsBuy—
10 June 2025D. Boral CapitalMaintainsBuy—
29 May 2025D. Boral CapitalMaintainsBuy—
10 Apr 2025D. Boral CapitalMaintainsBuy—
26 Mar 2025D. Boral CapitalMaintainsBuy—
25 Mar 2025HC Wainwright & Co.ReiteratesBuy—
21 Mar 2025Maxim GroupInitiatesBuy—
18 Feb 2025HC Wainwright & Co.ReiteratesBuy—
22 Jan 2025D. Boral CapitalMaintainsBuy—
14 Jan 2025D. Boral CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ANIX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ANIX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Anixa Biosciences, Inc. (ANIX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−10.9×

Cheaper than 93% of US stocks

Price / sales
—
Price / book
8.7×

Cheaper than 12% of US stocks

EV / EBITDA
−9.2×

Cheaper than 83% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−72.0%

Higher than 17% of US stocks

Return on assets
−41.9%

Higher than 10% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ANIX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ANIXAnixa Biosciences, Inc.$122.1M
85
VANIVivani Medical, Inc.$124.5M
40
GUTSFractyl Health, Inc.$123.7M
30
BDTXBlack Diamond Therapeutics, Inc.$126.6M
55
INOInovio Pharmaceuticals, Inc.$121.9M
44
GNLXGenelux Corp.$121.6M
19
HURATuHURA Biosciences, Inc.$121.4M
17

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Anixa Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ANIX news & analysis

Anixa Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference

PRNewsWire · 18 Aug 2026positive

Anixa Biosciences announced that management will present at the H.C. Wainwright 28th Annual Global Investment Conference. The presentation will highlight clinical progress including the lira-cel ovarian cancer CAR-T therapy advancing to its highest dose level with patients surpassing one year of survival, and final Phase 1 data for its breast cancer vaccine showing all primary endpoints were met with immune responses in 74% of participants.

Why it matters — ANIX watchers would track this as it provides an updated public overview of the company's clinical milestones and its collaborations with Moffitt Cancer Center and Cleveland Clinic.

FAQ

Frequently asked questions about ANIX stock

What is the ANIX stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Anixa Biosciences, Inc. have a median 12-month price target of $9.5, with estimates ranging from $7 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ANIX stock a buy right now?

Of the 4 analysts covering Anixa Biosciences, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Anixa Biosciences, Inc. 85 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ANIX?

As at 22 Aug 2026, Anixa Biosciences, Inc. ranks 85 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (93 of 100).

Will ANIX stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +156.4% from the last close, and Ticker Nerd's factor model ranks Anixa Biosciences, Inc. 85 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ANIX stock forecast for 2030?

No analyst covering Anixa Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ANIX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $14 over the next 12 months.

How has ANIX stock performed over the past year?

Anixa Biosciences, Inc. returned +25.6% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Anixa Biosciences, Inc. do?

Anixa Biosciences Inc. is a clinical-stage biotechnology company focused on developing therapies and vaccines to address critical unmet needs in oncology, particularly for the treatment and prevention of cancer.

What is the latest news on ANIX?

The most recent item we track (PRNewsWire, 18 Aug 2026): "Anixa Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference". Anixa Biosciences announced that management will present at the H.C. Wainwright 28th Annual Global Investment Conference. The presentation will highlight clinical progress including the lira-cel ovarian cancer CAR-T therapy advancing to its highest dose level with patients surpassing one year of survival, and final Phase 1 data for its breast cancer vaccine showing all primary endpoints were met with immune responses in 74% of participants.

Company

About Anixa Biosciences, Inc.

Anixa Biosciences Inc. is a clinical-stage biotechnology company focused on developing therapies and vaccines to address critical unmet needs in oncology, particularly for the treatment and prevention of cancer. Its primary programs include a chimeric antigen receptor T-cell (CAR-T) therapy targeting ovarian cancer through a novel FSHR-directed approach, designed to engineer patients' immune cells against solid tumors. The company also advances innovative vaccine platforms, such as an α-lactalbumin-based vaccine initially targeting triple negative breast cancer (TNBC), the most lethal form of breast cancer, with extensions to ovarian cancer and exploratory efforts in lung, colon, and prostate cancers. These immunopreventive technologies aim to harness the body's immune system for early detection and proactive intervention. Anixa Biosciences Inc. operates in the high-stakes field of immuno-oncology, emphasizing CAR-T therapeutics and preventive vaccines to improve outcomes in hard-to-treat malignancies. Founded in 1982 and headquartered in San Jose, California, it continues to advance its pipeline through clinical trials and intellectual property expansion.

CEO Dr. Amit Kumar Ph.D. · 4 employees · United States · https://www.anixa.com